Dear Visitor!

Marcus Hacker

A very warm welcome to the website of the Division of Nuclear Medicine, Department of Biomedical Imaging and Image-giuded Therapy at the Medical University of Vienna. The Division of Nuclear Medicine at the General Hospital of Vienna is one of Europe's largest and most important nuclear medical departments with more than 90 staff, its room and equipment set up, the treatment ward incorporating 8 systemised beds as well as its radiochemistry/pharmacy with cyclotron facility.

In the area of imaging diagnostics all procedures of conventional nuclear medicine such as thyroid, skeleton, lung, brain and heart examinations as well as inflammation diagnostics in SPECT and SPECT/CT-Technology are offered.

In addition, the department has PET/CT and PET/MR scanners, which are used in combination with a wide range of radiopharmaceuticals for individual and customised diagnosis and therapy concepts. This is of crucial importance for the close cooperation with the Comprehensive Cancer Center (CCC) and the numerous university hospitals.

The department further focuses on nuclear medicine treatments of thyroids, liver, prostate or neuroendocrine tumours using beta and alpha radiation emitters.

We look forward to being able to welcome you to our department and want to make your stay as pleasant as possible.

 

Univ.-Prof. Dr. med. Marcus Hacker
head of the division of Nuclear Medicine

Events

 

---English below--- Kommunikation soll den Zusammenhalt in der Abteilung erhöhen und unsere Wissenschaftler*innen und Klinker*innen motivieren. Dazu veranstalten wir Seminare von externen Sprecher*innen (Cheese&Crackers),...more

 
 

News

 
   

Wir gratulieren Céclie Philippe, Eva-Marie Klebermass sowie Chrysoula Vraka aus der Klinischen Abteilung für Nuklearmedizin zur Preisverleihung.

 
 

Neu identifizierte Biomarker könnten in Zukunft nebst bildgebender Verfahren zur nicht-invasiven Diagnostik von Patienten mit fortgeschrittenen Prostatakarzinomen eingesetzt werden.

 
 

In a research cooperation between the Division of Nuclear Medicine of the MeduniWien, Taiyuan, China and Beijing, China, the trend of cCFR with changing LVEF at rest was depicted for the first time.

 
 

Im Zuge der Medikamentenentwicklung für muskarinische Acetylcholinrezeptoren gelang es Wissenschaftler*innen der Klinischen Abteilung für Nuklearmedizin der Medizinischen Universität Wien (Dr. Marius Ozenil et al.) und der Universität Wien (Ass.-Prof. Mag. Dr. Verena Pichler) ein neues Nebenproduk

 
 

MedUni Wien unter den besten Universitäten auf dem Gebiet der Radiologie, Nuklearmedizin und medizinischen Bildgebung

 
 
 
 

Featured